Full-Text Search:
Home|About CNKI|User Service|中文
Add to Favorite Get Latest Update

The activity of special CTLs in diminishing CD55~(high) subgroup in human breast cancer MCF-7 cells

YANG Chao;CUI Zhichao;GUO Qingjun;LIU Yunjiang;WANG Shijie;Department of Breast Center,the Fourth Hospital,Hebei Medical University;Department of the First mammary,the People ’s Hospital of Tang Shan;Department of Educational Administration,Hebei Medical University;Department of Endoscope,the Fourth Hospital,Hebei Medical University;  
Objective To investigate the activities of cytokine induced killer cells( CIK cells) and specific cytotoxic T lymphocytes( CTL) in killing CD55highsubgroup in MCF-7 breast cancer cell line. Methods The killing effects of CIK cells,and specific CTLs in diminishing CD55highsubgroup cells were analyzed and compared with those of three chemotherapy drugs. First,the MCF-7 breast cancer cells were treated with different concentrations of three chemotherapeutic drugs,docetaxel,epirubicin and fluorouracil. Then immune cells were isolated from human peripheral blood and were induced to become CIK cells. They were then used to treat CD55highand CD55lowsubpopulations in MCF-7 cells. Finally,lymphocytes were isolated from surgical specimens of human axially lymph nodes,and were induced to become tumor-specific CTL in vitro. Their activities in killing CD55highand CD55lowsubpopulations in MCF-7 cells were measured as well. Results The killing rates of docetaxel,epirubicin and fluorouracil on CD55highsubgroup MCF-7 cells were much lower than on total MCF-7 cells.The killing rate of CIK cells on CD55highsubgroup cells was( 42. 72 ± 4. 36) %. The killing rates of specific CTLs on CD55high,CD55low,and total MCF-7 cells were( 52.86 ± 4. 45) %,( 22. 41 ± 2. 83) %,and( 21. 67 ± 4. 15) %,respectively. Conclusion Specific CTL possessed more effective killing effects on CD55highcells.
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©CNKI All Rights Reserved